Moreover, FAS and ACC1 play an essential role in the synthesis of de novo fatty acids and TGs in the liver, and FAS inhibitors have been used as a potential treatment for obesity and liver-related disorders62. Here, FAS is linked to obesity due to melanocortin 4 receptor deficiency.